Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT01745484 Completed - Clinical trials for Non-small-cell Lung Cancer

Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation

Start date: June 2012
Phase: N/A
Study type: Interventional

Overall objective of the study is to compare the use of SPECT in radiotherapy treatment planning with standard CT-based radiotherapy for stage I-III non-small-cell lung cancer patients

NCT ID: NCT01741636 Completed - Clinical trials for Stage IIIB Non-small Cell Lung Cancer

Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer

Start date: January 2013
Phase: N/A
Study type: Interventional

Survivorship Care Planning may improve overall well-being and quality of life of colorectal and lung cancer survivors

NCT ID: NCT01741506 Completed - Lung Cancer Clinical Trials

Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer

COPPVATS
Start date: March 2013
Phase: Phase 4
Study type: Interventional

The purpose of the study is: To estimate patients with lung cancers who will undergo surgery total haemostatic / thrombotic capacity pre, per-and postoperatively. To investigate whether prophylactic treatment with Low Molecular Weight Heparin (LMWH) affects the patient's potential hypercoagulability. To investigate whether there are differences in patients who will undergo Video Assisted Thorascopic Surgery (VATS) or open surgery in regards of impact of the coagulation system.

NCT ID: NCT01737502 Completed - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Start date: May 14, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.

NCT ID: NCT01733589 Completed - Clinical trials for Stage III Non-small-Cell Lung Cancer

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Start date: November 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas. Preclinical models have shown that Endostar may transiently "normalize" the tumor vasculature to make it more efficient for oxygen delivery, thereby providing a window of opportunity for enhanced sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT regimen in patients with unresectable stage III NSCLC.

NCT ID: NCT01729689 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers

Start date: November 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies cognitive behavioral therapy in treating anxiety in patients with stage IV non-small cell lung cancer and their caregivers. Cognitive behavioral therapy may reduce anxiety and improve the well-being and quality of life of patients who have stage IV non-small cell lung cancer and their caregivers.

NCT ID: NCT01727076 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Start date: February 15, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Recombinant interleukin-(IL)15 is a biological product, a protein, made naturally in the body and when made in the laboratory may help stimulate the immune system in different ways and stop tumor cells from growing.

NCT ID: NCT01726296 Completed - Clinical trials for Stage IIIB Non-small Cell Lung Cancer

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Start date: January 2013
Phase: N/A
Study type: Interventional

This clinical trial studies adherence to survivorship care guidelines in health care providers for non-small cell lung cancer or colorectal cancer survivor care. The completion of an educational intervention by health care providers may increase compliance and adherence to National Comprehensive Cancer Network guidelines for survivorship care.

NCT ID: NCT01725165 Completed - Clinical trials for Recurrent Lung Non-Small Cell Carcinoma

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Start date: November 28, 2012
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well surgery and/or radiation therapy or standard therapy and/or clinical observation works in treating patients with previously treated stage IV non-small cell lung cancer. Radiation therapy uses high energy x-rays to kill tumor cells. Giving surgery and/or radiation therapy may be more effective than standard therapy and/or clinical observation in patients with previously treated non-small cell lung cancer.

NCT ID: NCT01724801 Completed - Clinical trials for Non Small Cell Lung Cancer

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

BRAIN
Start date: October 14, 2012
Phase: Phase 3
Study type: Interventional

EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.